Mankind Pharma Limited Max Pain Analysis
What is Max Pain?
Max Pain theory states the underlying gravitates toward the strike where option writers face minimum collective loss at expiry. For MANKIND, that strike is ₹2,060. Spot at ₹2,186.1 is 6.12% above max pain — possible downward gravitational pull into expiry.
Max Pain Level
Mankind Pharma's max pain sits at ₹2060, the strike where option sellers incur the least total loss at expiry. This level often acts as a magnet for the spot price as expiry approaches, due to the concentration of open writer positions.
Spot vs Max Pain Gap
Spot trades at ₹2186.1, 6.12% above max pain, indicating a notable premium. This gap suggests a potential downward pull, as price gravitates toward areas of least financial resistance.
Shift Signal
The max pain level is unchanged from yesterday, signaling stable writer positioning and balanced call-put obligations around ₹2060. Minimal shift implies low reactive hedging pressure near term.
Expiry Bias
With 7 days to expiry, a gradual drift toward ₹2060 is expected, supported by open interest concentration. However, the magnet effect strengthens meaningfully only within the final 5 days, limiting near-term predictability.
Trader Note
If days to expiry fall to 5 or fewer, consider premium decay strategies targeting strikes around ₹2060, especially short strangles or credit spreads.
Data as of 2026-04-21